The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Background HER2-positive metastatic breast cancer is incurable and new treatments are
needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the
treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …